Stephens Inc. AR Cuts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stephens Inc. AR decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 2.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,194 shares of the medical research company’s stock after selling 256 shares during the quarter. Stephens Inc. AR’s holdings in Thermo Fisher Scientific were worth $6,021,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TMO. Widmann Financial Services Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $26,000. Mystic Asset Management Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Lee Financial Co acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $32,000. Sumitomo Mitsui Financial Group Inc. boosted its position in Thermo Fisher Scientific by 141.7% during the fourth quarter. Sumitomo Mitsui Financial Group Inc. now owns 58 shares of the medical research company’s stock worth $38,000 after acquiring an additional 34 shares during the last quarter. Finally, Lloyd Advisory Services LLC. boosted its holdings in Thermo Fisher Scientific by 294.1% in the 1st quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 87.48% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $545.60, for a total value of $5,456,000.00. Following the completion of the transaction, the chief executive officer now owns 183,373 shares in the company, valued at approximately $100,048,308.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, COO Michel Lagarde sold 13,030 shares of the firm’s stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $565.04, for a total transaction of $7,362,471.20. Following the sale, the chief operating officer now directly owns 15,758 shares of the company’s stock, valued at approximately $8,903,900.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $545.60, for a total transaction of $5,456,000.00. Following the sale, the chief executive officer now directly owns 183,373 shares in the company, valued at $100,048,308.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,561 shares of company stock worth $23,557,413. 0.43% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wells Fargo & Company lowered shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $605.00 to $525.00 in a report on Monday, April 25th. StockNews.com initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Barclays reduced their price target on shares of Thermo Fisher Scientific from $675.00 to $630.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $653.54.

Thermo Fisher Scientific Trading Up 1.5 %

NYSE TMO opened at $581.93 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.56 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $497.83 and a 52 week high of $672.34. The stock has a market capitalization of $227.80 billion, a PE ratio of 30.34, a price-to-earnings-growth ratio of 1.93 and a beta of 0.82. The firm has a 50 day moving average of $543.36 and a two-hundred day moving average of $558.57.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last issued its earnings results on Thursday, April 28th. The medical research company reported $7.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.17 by $1.08. Thermo Fisher Scientific had a net margin of 18.49% and a return on equity of 25.33%. The business had revenue of $11.82 billion during the quarter, compared to analysts’ expectations of $10.66 billion. During the same quarter in the prior year, the business posted $7.21 EPS. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 22.63 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Thursday, September 15th will be given a dividend of $0.30 per share. The ex-dividend date is Wednesday, September 14th. This represents a $1.20 dividend on an annualized basis and a yield of 0.21%. Thermo Fisher Scientific’s payout ratio is currently 6.26%.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.